ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2023, 'Hyperuricaemia and Chronic Kidney Disease', in Management of Chronic Kidney Disease, Springer International Publishing, pp. 81 - 97, http://dx.doi.org/10.1007/978-3-031-42045-0_7
,2014, 'Erythropoiesis stimulating agent resistance', in Advances in Drug Resistance Research, pp. 120 - 135
,2013, 'How do clinical outcomes of automated peritoneal dialysis compare with those of continuous ambulatory peritoneal dialysis?', in Issues in Dialysis, pp. 85 - 102
,2013, 'An overview of erythropoietin therapy', in Erythropoietin: Human Production, Potential Uses and Adverse Effects, pp. 31 - 53
,2013, 'Peritoneal transport status: A risk factor for peritoneal dialysis', in Peritoneal Dialysis: Types, Procedures and Risks Factors, pp. 69 - 94
,2012, 'How do clinical outcomes of automated peritoneal dialysis compare with those of continuous ambulatory peritoneal dialysis?', in Issues in Dialysis, pp. 85 - 102
,2010, 'Interventions for erythropoietin-resistant anaemia in dialysis patients', in Badve SV (ed.), , John Wiley & Sons, Ltd, http://dx.doi.org/10.1002/14651858.cd006861.pub2
,2024, 'Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)', American Journal of Respiratory and Critical Care Medicine, 209, pp. 1141 - 1151, http://dx.doi.org/10.1164/rccm.202308-1426OC
,2024, 'Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', American Journal of Kidney Diseases, 83, pp. 350 - 359.e1, http://dx.doi.org/10.1053/j.ajkd.2023.07.023
,2024, 'Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial', Kidney International Reports, 9, pp. 347 - 355, http://dx.doi.org/10.1016/j.ekir.2023.11.024
,2024, 'Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data', The Lancet Regional Health - Western Pacific, 43, http://dx.doi.org/10.1016/j.lanwpc.2023.100988
,2024, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Kidney International Reports, 9, pp. 312 - 322, http://dx.doi.org/10.1016/j.ekir.2023.11.022
,2024, 'WCN24-2313 LONG-TERM SAFETY OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS', Kidney International Reports, 9, pp. S562 - S563, http://dx.doi.org/10.1016/j.ekir.2024.02.1183
,2023, 'The outcomes of patients with kidney failure due to focal segmental glomerulosclerosis (FSGS) in Australia and New Zealand: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA)', PLoS ONE, 18, http://dx.doi.org/10.1371/journal.pone.0293721
,2023, 'Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis', American Journal of Kidney Diseases, 82, pp. 543 - 558, http://dx.doi.org/10.1053/j.ajkd.2023.04.003
,2023, 'Kidney function and the comparative effectiveness and safety of direct oral anticoagulants vs. warfarin in adults with atrial fibrillation: a multicenter observational study', European Heart Journal - Quality of Care and Clinical Outcomes, 9, pp. 621 - 631, http://dx.doi.org/10.1093/ehjqcco/qcac069
,2023, 'Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease', Kidney Medicine, 5, http://dx.doi.org/10.1016/j.xkme.2023.100691
,2023, 'SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review', Endocrine Connections, 12, http://dx.doi.org/10.1530/EC-23-0005
,2023, 'A meta-analysis of GFR slope as a surrogate endpoint for kidney failure', Nature Medicine, 29, pp. 1867 - 1876, http://dx.doi.org/10.1038/s41591-023-02418-0
,2023, 'Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada', Kidney Medicine, 5, http://dx.doi.org/10.1016/j.xkme.2023.100675
,2023, 'Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?', Nephrology, 28, pp. 97 - 108, http://dx.doi.org/10.1111/nep.14130
,2023, 'Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD', Clinical journal of the American Society of Nephrology : CJASN, 18, pp. 183 - 192, http://dx.doi.org/10.2215/CJN.0000000000000050
,2023, 'Development and Validation of a Predictive Risk Algorithm for Bleeding in Individuals on Long-term Hemodialysis: An International Prospective Cohort Study (BLEED-HD)', Canadian Journal of Kidney Health and Disease, 10, http://dx.doi.org/10.1177/20543581231169610
,2023, 'Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial', Journal of the American Society of Nephrology, 34, pp. 140 - 140, http://dx.doi.org/10.1681/asn.20233411s1140b
,2023, 'Iron Biomarkers and Effects of Canagliflozin in Patients with Type 2 Diabetes and CKD: A Post Hoc Analysis of the CREDENCE Trial', Journal of the American Society of Nephrology, 34, pp. 140 - 140, http://dx.doi.org/10.1681/asn.20233411s1140c
,2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', Journal of the American Society of Nephrology, 34, pp. 367 - 367, http://dx.doi.org/10.1681/asn.20233411s1367a
,2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Journal of the American Society of Nephrology, 34, pp. 373 - 373, http://dx.doi.org/10.1681/asn.20233411s1373a
,2022, 'Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice', Heart Lung and Circulation, 31, pp. 1604 - 1611, http://dx.doi.org/10.1016/j.hlc.2022.09.003
,2022, 'Study protocol for Vascular Access outcome measure for function: a vaLidation study In hemoDialysis (VALID): A multi-center, multinational validation study to assess the accuracy and feasibility of measuring vascular access function in clinical practice', BMC Nephrology, 23, http://dx.doi.org/10.1186/s12882-022-02987-1
,2022, 'Canagliflozin and atrial fibrillation in type 2 diabetes mellitus: A secondary analysis from the CANVAS Program and CREDENCE trial and meta-analysis', Diabetes, Obesity and Metabolism, 24, pp. 1927 - 1938, http://dx.doi.org/10.1111/dom.14772
,2022, 'Representativeness of the PDOPPS cohort compared to the Australian PD population', Peritoneal Dialysis International, 42, pp. 403 - 414, http://dx.doi.org/10.1177/08968608211056242
,2022, 'Sex differences in chronic kidney disease prevalence in Asia: A systematic review and meta-analysis', Clinical Kidney Journal, 15, pp. 1144 - 1151, http://dx.doi.org/10.1093/ckj/sfac030
,2022, 'International Icodextrin Use and Association with Peritoneal Membrane Function, Fluid Removal, Patient and Technique Survival', Kidney360, 3, pp. 872 - 882, http://dx.doi.org/10.34067/KID.0006922021
,2022, 'Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis', Journal of Nephrology, 35, pp. 1159 - 1170, http://dx.doi.org/10.1007/s40620-022-01268-2
,2022, 'Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD', Journal of the American Society of Nephrology, 33, pp. 59 - 76, http://dx.doi.org/10.1681/ASN.2021040554
,2022, 'Treatment preferences for primary membranous nephropathy: Results of a multinational survey among nephrologists in the South Asia Pacific region', Nephrology, 27, pp. 35 - 43, http://dx.doi.org/10.1111/nep.13953
,2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', Journal of the American Society of Nephrology, 33, pp. 297 - 298, http://dx.doi.org/10.1681/asn.20223311s1297c
,2022, 'Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease.', NEJM Evid, 1, pp. EVIDoa2100021, http://dx.doi.org/10.1056/EVIDoa2100021
,2021, 'Recent evidence on the effect of treatment of metabolic acid on the progression of kidney disease', Current Opinion in Nephrology and Hypertension, 30, pp. 467 - 473, http://dx.doi.org/10.1097/MNH.0000000000000728
,2021, 'Editor's note', Internal Medicine Journal, 51, pp. 1368, http://dx.doi.org/10.1111/imj.15462
,2021, 'Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial', Diabetes, Obesity and Metabolism, 23, pp. 1420 - 1425, http://dx.doi.org/10.1111/dom.14351
,2021, 'Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease', Current Opinion in Nephrology and Hypertension, 30, pp. 346 - 352, http://dx.doi.org/10.1097/MNH.0000000000000699
,2021, 'A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes', Kidney International Reports, 6, pp. 695 - 705, http://dx.doi.org/10.1016/j.ekir.2020.12.019
,2021, 'Dietary Phosphate Consumption in Australians With Stages 3b and 4 Chronic Kidney Disease', Journal of Renal Nutrition, 31, pp. 155 - 163, http://dx.doi.org/10.1053/j.jrn.2020.02.007
,2021, 'The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes', Diabetes, Obesity and Metabolism, 23, pp. 763 - 773, http://dx.doi.org/10.1111/dom.14281
,2021, 'Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis—International Results from PDOPPS', Kidney International Reports, 6, pp. 313 - 324, http://dx.doi.org/10.1016/j.ekir.2020.11.021
,2021, 'Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials', The BMJ, 372, http://dx.doi.org/10.1136/bmj.m4573
,2021, 'POS-311 POLYPHARMACY IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HIGH PROGRESSION RISK', Kidney International Reports, 6, pp. S134 - S134, http://dx.doi.org/10.1016/j.ekir.2021.03.327
,2020, 'A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)', Journal of the American Society of Nephrology, 31, pp. 2653 - 2666, http://dx.doi.org/10.1681/ASN.2020040411
,2020, 'Assessment of dietary sodium intake using the scored salt questionnaire in autosomal dominant polycystic kidney disease', Nutrients, 12, pp. 1 - 14, http://dx.doi.org/10.3390/nu12113376
,